活性アミンのACTH放出に及ぼす影響:その2, in vitroでのACTH放出活性と下垂体前葉のcyclic 3′, 5′ adenosine monophosphate含量に及ぼす効果との相関について
スポンサーリンク
概要
- 論文の詳細を見る
In the first report, we demonstrated that the biogenic amines noradrenaline (NA), dopamine (DA) and serotonin (5HT), can act directly on the rat anterior pituitary to increase ACTH release in vitro, using a revised in vitro method for the assay of corticotropin releasing factor (CRF) activity developed in our laboratory. Cyclic 3', 5' adenosine monophosphate (cyclic AMP) has been implicated as a mediator of many hormonal actions, including the effect of hypothalamic releasing hormones on the release of pituitary hormones. Therefore, ACTH release induced by biogenic amines in vitro may be mediated through cyclic AMP. Based on these considerations, we studied the effect of biogenic amines on the cyclic AMP content in the rat anterior pituitary and considered the correlation of ACTH release and cyclic AMP increase stimulated in vitro by biogenic amines. Furthermore, we also considered the correspondence between the changes in the two parameters induced by some amine inhibitors and dexamethasone (DX). <BR>After two paired rat hemipituitaries were preincubated in 2 ml of Krebs-Ringer bicarbonate buffer (KRB) containing 0.2% glucose and 10<SUP>-2</SUP>M theophylline at 37°C for 30min. under a moist atmosphere of 95% 02 and 5% CO<SUB>2</SUB>, the medium was replaced with 2 ml of fresh medium containing the test substances and ascorbic acid (1 mg/ml) to prevent oxidative degradation of amines. Incubation was then carried out for an additional 15 min. Paired controls were employed throughout. The incubation was terminated by freezing the incubated pituitaries on alminium foil immersed in dry ice and acetone. Frozen tissues were homogenized in ice cold 6% trichloroacetic acid and denatured protein was removed by centrifugation. Precipitates were dissolved in 1 N NaOH and assayed for protein by Lowry's method<SUP>8</SUP>). Supernatants were washed with cold water-saturated ether and cyclic AMP was determined by the competitive protein binding assay of Gilman<SUP>6</SUP>) using the binding protein obtained from rat liver according to the method of Kumon et al.<SUP>5</SUP>) or by the radioimmunoassay of Steiner et al.<SUP>7</SUP>) Both methods gave comparable values using the same tissue. The results were expressed as nanomoles/gram of tissue protein or percentage of paired control. The system and method for measuring ACTH releasing activity were the same as described previously<SUP>1</SUP>). The paired comparison Student's t test was used for statistical analysis. <BR>The following results were obtained : <BR>1) NA increased cyclic AMP content in the pituitary at a concentration of 4 × 10<SUP>-4</SUP>M which was the same concentration at which it stimulated ACTH release from the pituitary in vitro. However, it was ineffective at 4 × 10<SUP>-5</SUP>M, which was also the case in stimulating ACTH release. Furthermore, when reserpine pretreated rat pituitaries were used, (17 hrs before decapitation, 1 mg/rat, i.p.) a concentration of 4 × 10<SUP>-5</SUP>M of NA, which was capable of stimulating ACTH release, also increased pituitary cyclic AMP content. These effects of NA on both pituitary ACTH release and cyclic AMP content were inhibited by the β blocker propranolol, but not by the a blocker phentolamine. In spite of addition from the preincubation period, DX had no effect on either increasing ACTH release or cyclic AMP in response to NA. <BR>2) 5HT increased both pituitary ACTH release and cyclic AMP at a concentration of 3.3 × 10<SUP>-4</SUP>M. Even at a lower concentration (3.3 × 10<SUP>-5</SUP>M), 5HT stimulated the ACTH release significantly and was also found to tend to increase the cyclic AMP content to 145% of that of the control although this was not significant. These effects of 5HT on both pituitary ACTH release and cyclic AMP content were inhibited by the same concentration of the serotonergic blocker methysergide,
- 日本内分泌学会の論文
著者
-
山村 雄一
大阪大学医学部
-
花崎 信夫
大阪大学医学部第三内科
-
矢野 三郎
大阪大学医学部第三内科
-
植村 泰三
大阪大学医学部第3内科
-
矢野 三郎
大阪大学医学部堂野前内科
-
花崎 信夫
大阪大学医学部第3内科
関連論文
- 9.当教室における肺癌症例の検討 : 第18回支部活動 : 関西支部
- Bronchialcarcinoidの2例 : 症例
- リニアック治療後の末梢血リンパ球の変動 : 肺癌患者と他の癌患者との比較検討
- 46 III, IV期肺癌でのBCG-CWSあるいは, Nocardia rubra-CWS(N-CWS)投与による延命効果の分析
- 肺癌I期, II期切除症例に対するAdjuvant ImmunotherapyとしてのBCG-CWS投与の効果
- 33. 興味ある進展を示した癌性リンパ管症の一例 : 第24回日本肺癌学会関西支部会
- 20. 肺癌末期患者のECG変化とその予後 : 第24回日本肺癌学会関西支部会
- まとめ : 日本ビタミン学会第30回大会シンポジウム(脂溶性ビタミンに関する最近の進歩)
- はじめに : 日本ビタミン学会第30回大会シンポジウム(脂溶性ビタミンに関する最近の進歩)
- 化学性発癌物質によるウサギの実験的肺癌ならびに胸腺摘除の影響 : 第14回日本肺癌学会総会演題抄録
- 12. 「CWSによる癌性胸水に対する免疫療法 : 原発巣不明の一症例」 : 第24回日本肺癌学会関西支部会
- 6.進行肺癌症例診療の当科における現状 : 第20回肺癌学会関西支部会
- F-8. 化学性発癌物質によるウサギの実験的肺癌 : 発癌・増殖・組織 I
- 2. 真菌多糖体抗原(真菌アレルギー 第21回日本アレルギー学会総会シンポジウム II)
- 当教室における肺癌症例診療の現状 : 第14回日本肺癌学会総会演題抄録
- Aspergillus fumigatsu の菌体蛋白及び多糖体の基礎的並びに臨床的研究(第6回 近畿アレルゲン研究会)
- III-3) 免疫療法(III. 小児がん治療の最近の進歩)(悪性腫瘍の治療を中心として)
- 生物(化学教育の進め方 III : 化学像)
- 分子病の病態 : 異常ヘモグロビンをモデルとして
- アンジオテンシン-スキンテスト
- 巨大な非細菌性血栓性心内膜炎により急性心不全をきたした胆管癌の1例
- 慢性疾患ステロイド治療時の副腎皮質機能抑制に及ぼすステロイド製剤の種類,投与量,投与方法の影響について
- 追加発言 高コレステロール血症と肝のコレステロール代謝調節とくに細胞内転送機構について
- 皮内反応にかんする実験的並びに臨床的研究 第1報 : 皮内反応の規準と皮内反応抗原の抽出精製について
- 続発性副腎不全の予防および治療に関する実験的研究
- Secondary Aldosteronismに関する実験的臨床的研究
- 選択的IgA欠損症の2症例 : 末梢血リンパ球でのIgA産生異常
- (6)癌免疫療法の展望
- 第53回総会特別講演 : II. ミコバクテリアと細胞性免疫
- 神経性食思不振症の内分泌学的検討 とくに肥満症との対比
- A Novel Method for Preparations of Several Hapten-Protein Conjugates
- Studies on Lipid Metabolism in Experimental Diabetic Rat
- 活性アミンのラット下垂体前葉CAMP含量に及ぼす影響
- 活性アミンのACTH放出に及ぼす影響:その1, 特にin vitroでの下垂体前葉直接作用について
- 活性アミンのACTH放出に及ぼす影響:その2, in vitroでのACTH放出活性と下垂体前葉のcyclic 3′, 5′ adenosine monophosphate含量に及ぼす効果との相関について
- GlycyrrhizinのCorticoid作用の本態に関する実験的研究
- Chemocorticoids測定法に関する研究:(I) β-glucuronidase加水分解法による尿中, 血中結合型chemo-corticoidsの測定法に就て
- ツベルクリン活性ペプチド(TAP)およびその各種誘導体のツベルクリン力価の比較
- Regulation of Serum Cholesterol Level by the Liver:Relationship with Development of Hypercholesterolemia, Aging and Genetic Factor
- Studies on the Structure of Immunoglobulin A from Serum of a Patient with Multiple Myeloma
- タイトル無し
- Enzymatic Fragmentation of Human IgM
- Antihypertensive and Hypouricemic Effects of Tienilic Acid in Hypertensive Patients with Hyperuricemia